Drug intelligence / Profile preview

MRCL3 siRNA

Development stage
Preclinical
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

MRCL3 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Myosin Regulatory Light Chain (MRCL3), also known as MYL12A. MRCL3 is a regulatory protein involved in essential cellular processes such as cytokinesis, receptor capping, and cell locomotion. In preclinical models of pancreatic cancer, specifically using BxPC3 cells, the application of MRCL3 siRNA has been shown to significantly inhibit cell proliferation and induce apoptosis (measured by an increase in the Sub G1 population). The mechanism of action involves the modulation of the AP-1 transcriptional pathway, specifically by increasing the expression of c-Jun and blocking the expression of c-Fos. This experimental agent is being investigated as a potential molecular target for the treatment of pancreatic cancer, a disease with limited therapeutic options.

Other names
Myosin Regulatory Light Chain 3 siRNAMYL12A siRNAMYL-12A siRNAMYL 12A siRNAMyosin Regulatory Light Chain Silencing RNA
02

Targets

MYL12A (Myosin regulatory light chain 12A)

Beyond the preview

Go deeper on MRCL3 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRCL3 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call